The purpose of this quality improvement initiative is to explore whether an electronic medical records-based templated progress note for polycythemia vera (PV) in addition to a standard-of-care pharmacist-collaborative ropeginterferon alfa-2b titration service is feasible, acceptable, and appropriate for clinicians who manage PV.
None
Clinicians who do not have an outpatient hematology or medical oncology clinic within Mass General Brigham.
Clinicians who do not utilize the EPIC electronic medical record (EMR) System as their method of patient progress note documentation.
Single group
Standardized progress note
BehavioralPilot intervention will include a standardized progress note for PV patient visits in addition to a standard-of-care opt-in for pharmacist-led titration for patients on ropeginterferon alfa-2b.
Feasibility of intervention
Number of participants that are eligible who enroll in this initiative and rating of feasibility by a single question on a 5-point Likert scale with score \>3 indicating higher feasibility
Acceptibility of intervention
Acceptability measured by a single question on a 5-point Likert scale with score \>3 indicating higher acceptability.
Appropriateness of intervention
Appropriateness measured by a single question on a 5-point Likert scale with score \>3 indicating higher appropriateness.
Rate of progress note use
Rate of progress note use per total number of PV patient visits over 12 month study period.
Rate of symptoms documentation
Rate of symptom documentation per total number of PV patient visits
Rate of cytoreductive therapy change or initiation
Rate of cytoreductive therapy change or initiation by clinician per total number of PV patients who are eligible for a therapy change or initiation.
Rate of referrals or second opinion consultations with a leukemia specialist
Rate of referrals or second opinion consultations with a leukemia specialist per total number of PV patients evaluated over study period
Click on the lead sponsor to view all of their trials.
Massachusetts General Hospital
Lead sponsor
PharmaEssentia
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
